Background
The efficacy of broadly neutralizing antibodies (bNAbs) is affected by the genetic diversity of HIV-1 and the ongoing escape from autologous neutralizing Abs at the population level. We investigated the current state of neutralization sensitivity of recent transmitted/founder (T/F) variants, with a focus on subtype B and CRF02_AG, the predominant clades in North America, Western Europe and Western Africa.
Methods
We collected early infection samples from participants enrolled in the French ANRS PRIMO cohort between 2019 and 2022. We analyzed neutralization sensitivity to 9 bNAbs, targeting the CD4 binding site (VRC01, 3BNC117, N6), V1/V2 apex (PG16, PGT145), V3-glycan (10-1074, PGT121, 8ANC195), and the MPER region (10E8). We compared them with viruses from earlier epidemic periods, starting from 1988 for B viruses (N=40) and 1997 for CRF02_AG (N=33).
Results
We expanded our representative T/F panel to 125 pseudotyped viruses, including 52 recent. For subtype B (N=59), we found a progressive loss of susceptibility over time for 7 bNAbs tested (all p<0.01), but not for 10E8. Among recent isolates, a resistant phenotype defined by an IC50 >1mg/mL was found in 26% for 3BNC117, 41% for 10-1074, 59% for PGT121 and 74% for VRC01. There was a positive correlation between IC50 values and divergence from consensus B for most antibodies (R=0.29–0.46, p<0.05), suggesting that increasing viral diversity is a major driver of resistance to neutralization. For CRF02_AG (N=45), IC50 values increased over time for VRC01 (p=0.009), 3BNC117 (p=0.012), and 8ANC195 (p=0.017), while for other bNAbs—including apex- and MPER-directed bNAbs—they remained stable. Correlations between genetic divergence and resistance were observed only for those 3 bNAbs, suggesting an epitope-specific resistance evolution. However, recent viruses with IC50 >1mg/mL were even more frequent (3BNC117: 33%, 10-1074: 41%, PGT121: 67%, VRC01: 75%). Among other genotypes, this resistance was similarly high (3BNC117: 33%, VRC01: 82%). N6 was the best in class, neutralizing 85% of all recent viruses at IC50 <1mg/mL.
Conclusions
This most up-to-date panel of T/F viruses shows a concerning continuous increase in resistance to bNAbs, without previous exposure. Correlation of in vitro results with clinical efficacy in ongoing trials is needed, along with continuous surveillance of neutralization sensitivity to guide the rational design and clinical deployment of bNAb-based prevention, treatment and cure strategies.